 CARMINE Therapeutics, a biotech firm developing non-viral gene therapies for rare diseases, on Wednesday said it has signed a US900 million research agreement with Takeda Pharmaceutical to discover, develop and commercialise two rare-disease drugs. Read more at The Business Times. 